DE2306107A1 - Verfahren zur entfernung von hepatitisantigen aus einer proteinfraktion - Google Patents
Verfahren zur entfernung von hepatitisantigen aus einer proteinfraktionInfo
- Publication number
- DE2306107A1 DE2306107A1 DE2306107A DE2306107A DE2306107A1 DE 2306107 A1 DE2306107 A1 DE 2306107A1 DE 2306107 A DE2306107 A DE 2306107A DE 2306107 A DE2306107 A DE 2306107A DE 2306107 A1 DE2306107 A1 DE 2306107A1
- Authority
- DE
- Germany
- Prior art keywords
- protein
- antigen
- solution
- polyethylene glycol
- precipitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 85
- 208000006454 hepatitis Diseases 0.000 title claims description 44
- 231100000283 hepatitis Toxicity 0.000 title claims description 43
- 239000000427 antigen Substances 0.000 title claims description 35
- 102000036639 antigens Human genes 0.000 title claims description 34
- 108091007433 antigens Proteins 0.000 title claims description 34
- 239000002202 Polyethylene glycol Substances 0.000 claims description 82
- 229920001223 polyethylene glycol Polymers 0.000 claims description 82
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 68
- 239000000243 solution Substances 0.000 claims description 64
- 239000002244 precipitate Substances 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 108010049003 Fibrinogen Proteins 0.000 claims description 38
- 102000008946 Fibrinogen Human genes 0.000 claims description 38
- 229940012952 fibrinogen Drugs 0.000 claims description 38
- 238000001556 precipitation Methods 0.000 claims description 38
- 239000000872 buffer Substances 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 25
- 235000002639 sodium chloride Nutrition 0.000 claims description 24
- 239000012141 concentrate Substances 0.000 claims description 23
- 239000006228 supernatant Substances 0.000 claims description 23
- 108010088751 Albumins Proteins 0.000 claims description 20
- 102000009027 Albumins Human genes 0.000 claims description 20
- 108010074605 gamma-Globulins Proteins 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 108010094028 Prothrombin Proteins 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 9
- 150000002500 ions Chemical class 0.000 claims description 9
- 102100027378 Prothrombin Human genes 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 229940039716 prothrombin Drugs 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 6
- 239000007979 citrate buffer Substances 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000002753 trypsin inhibitor Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 108090000935 Antithrombin III Proteins 0.000 claims description 2
- 102000004411 Antithrombin III Human genes 0.000 claims description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 108010075016 Ceruloplasmin Proteins 0.000 claims description 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 2
- 108010051456 Plasminogen Proteins 0.000 claims description 2
- 102000013566 Plasminogen Human genes 0.000 claims description 2
- 102000009488 Thyroxine-Binding Proteins Human genes 0.000 claims description 2
- 108010048889 Thyroxine-Binding Proteins Proteins 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 2
- 229960005348 antithrombin iii Drugs 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 230000036425 denaturation Effects 0.000 claims description 2
- 238000004925 denaturation Methods 0.000 claims description 2
- 238000001226 reprecipitation Methods 0.000 claims description 2
- 239000010865 sewage Substances 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- VTMHBUDWQBDMQS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OCC(N)(CO)CO.OC(=O)CC(O)(C(O)=O)CC(O)=O VTMHBUDWQBDMQS-UHFFFAOYSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 239000005695 Ammonium acetate Substances 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 229940043376 ammonium acetate Drugs 0.000 claims 1
- 235000019257 ammonium acetate Nutrition 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 34
- 102100026735 Coagulation factor VIII Human genes 0.000 description 30
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 241000700605 Viruses Species 0.000 description 20
- 238000002156 mixing Methods 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 10
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000005194 fractionation Methods 0.000 description 9
- 208000002672 hepatitis B Diseases 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 5
- 241000723873 Tobacco mosaic virus Species 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 4
- 108010054218 Factor VIII Proteins 0.000 description 4
- 102000001690 Factor VIII Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 229960000301 factor viii Drugs 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241001447067 Maize red stripe virus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- -1 alpha macroglobulin Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- VUSHQLWDOJFSGF-UHFFFAOYSA-L disodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate chloride Chemical compound [Na+].[Na+].Cl.[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O VUSHQLWDOJFSGF-UHFFFAOYSA-L 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YBHYYFYQHRADCQ-UHFFFAOYSA-N 2-aminoacetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O YBHYYFYQHRADCQ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000196477 Beet mosaic virus Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010032597 Cohn fraction II Proteins 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000012860 Horse disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BQJJOBNOUMMQCD-UHFFFAOYSA-L [Cl-].[Na+].C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-].[Na+].NCC(=O)O Chemical compound [Cl-].[Na+].C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-].[Na+].NCC(=O)O BQJJOBNOUMMQCD-UHFFFAOYSA-L 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003171 anti-complementary effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229940074995 bromine Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- LBTKWJDQDQBZMV-UHFFFAOYSA-K trisodium 2-aminoacetic acid 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].NCC(=O)O.[Na+].[Na+] LBTKWJDQDQBZMV-UHFFFAOYSA-K 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23521172A | 1972-03-16 | 1972-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2306107A1 true DE2306107A1 (de) | 1973-09-27 |
Family
ID=22884566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2306107A Pending DE2306107A1 (de) | 1972-03-16 | 1973-02-08 | Verfahren zur entfernung von hepatitisantigen aus einer proteinfraktion |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3790552A (enrdf_load_stackoverflow) |
| AT (1) | AT321465B (enrdf_load_stackoverflow) |
| BE (1) | BE796770A (enrdf_load_stackoverflow) |
| CA (1) | CA1061251A (enrdf_load_stackoverflow) |
| DE (1) | DE2306107A1 (enrdf_load_stackoverflow) |
| DK (1) | DK133292C (enrdf_load_stackoverflow) |
| FR (1) | FR2175969B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1375811A (enrdf_load_stackoverflow) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3951937A (en) * | 1973-12-20 | 1976-04-20 | The Community Blood Council Of Greater New York, Inc. | Large scale purification of hepatitis type B antigen using polyethylene glycol |
| DE2602892A1 (de) * | 1976-01-27 | 1977-07-28 | Community Blood Council | Konzentriertes hepatitis-b-oberflaechenantigen enthaltende masse und verfahren zu ihrer herstellung |
| DK144731C (da) | 1976-07-30 | 1982-10-18 | Nordisk Insulinlab | Fremgangsmaade til isolering af proteinhormoner stammende fra humant hypofysevaev |
| DK25877A (da) * | 1977-01-21 | 1978-08-15 | Nordisk Insulinlab | Fremgangsmaade til udvinding af renset albumin fra blodplasma |
| US4197238A (en) * | 1977-04-12 | 1980-04-08 | The Green Cross Corporation | Method of preparation of human albumin using polyethylene glycol |
| DE2750045A1 (de) * | 1977-11-09 | 1979-05-10 | Behringwerke Ag | Verfahren zur entfernung von detergentien aus virusantigensuspensionen |
| US4164496A (en) * | 1978-08-23 | 1979-08-14 | American National Red Cross | Preparation of albumin using PEG and EDTA |
| US4395395A (en) * | 1979-05-21 | 1983-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of non-A, non-B hepatitis associated antigen |
| FR2483779A1 (fr) * | 1980-06-05 | 1981-12-11 | Synthelabo | Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins |
| US4835257A (en) * | 1984-07-07 | 1989-05-30 | Armour Pharma Gmbh | Process for preparing gamma globulin suitable for intravenous administration using peg and a citrate buffer |
| US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
| US4684723A (en) * | 1985-09-11 | 1987-08-04 | Miles Laboratories, Inc. | Method of separating proteins from aqueous solutions |
| US4833233A (en) * | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
| US5525519A (en) * | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
| CA2677532A1 (en) * | 2007-02-06 | 2008-08-14 | Incept, Llc | Polymerization with precipitation of proteins for elution in physiological solution |
| EP2121753A2 (en) * | 2007-02-14 | 2009-11-25 | Amgen, Inc | Method of isolating antibodies by precipitation |
-
1972
- 1972-03-16 US US00235211A patent/US3790552A/en not_active Expired - Lifetime
-
1973
- 1973-02-08 DE DE2306107A patent/DE2306107A1/de active Pending
- 1973-02-15 DK DK82273*#A patent/DK133292C/da active
- 1973-03-01 AT AT184173A patent/AT321465B/de not_active IP Right Cessation
- 1973-03-13 FR FR7308875A patent/FR2175969B1/fr not_active Expired
- 1973-03-13 GB GB1213873A patent/GB1375811A/en not_active Expired
- 1973-03-14 BE BE128796A patent/BE796770A/xx unknown
- 1973-03-16 CA CA166,295A patent/CA1061251A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AT321465B (de) | 1975-04-10 |
| DK133292C (da) | 1976-09-27 |
| US3790552A (en) | 1974-02-05 |
| BE796770A (fr) | 1973-07-02 |
| DK133292B (da) | 1976-04-26 |
| FR2175969A1 (enrdf_load_stackoverflow) | 1973-10-26 |
| FR2175969B1 (enrdf_load_stackoverflow) | 1977-08-12 |
| GB1375811A (enrdf_load_stackoverflow) | 1974-11-27 |
| CA1061251A (en) | 1979-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Woodin | Purification of the two components of leucocidin from Staphylococcus aureus | |
| DE2306107A1 (de) | Verfahren zur entfernung von hepatitisantigen aus einer proteinfraktion | |
| DE2751717C2 (enrdf_load_stackoverflow) | ||
| DE3734923C1 (de) | Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt | |
| DE2049515C3 (de) | Impfstoff gegen Vinishepatitis und Verfahren zu seiner Herstellung | |
| DE2801123C2 (de) | Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates | |
| DE2548636A1 (de) | Antiseren und antikoerper mit spezifischer wirkung gegen krebszellenproteine, verfahren zu ihrer herstellung und arzneipraeparate | |
| DE2624815B2 (de) | Herstellung einer injizierbaren, stromafreien und von Plasmaproteinen freien Hämoglobinlösung | |
| CH629668A5 (de) | Verfahren zum reinigen von hepatitis-b-antigen. | |
| DE2817871A1 (de) | Verfahren und vorrichtung zur abtrennung und reinigung von proteinen durch chromatographie | |
| DE69631229T2 (de) | Herstellung von virusinaktivierten intravenös injektierbaren Globulin aus Immunserum | |
| DE69833256T2 (de) | Methode zur entfernung von endotoxinen aus impstoffen | |
| DE2127159A1 (de) | Verfahren zur Fraktionierung von Plasmaproteinen | |
| EP0124896B1 (de) | Verfahren zur Gewinnung von Viren bzw. Virusantigenen und deren Anwendung in Diagnose und Therapie (Impfstoff) | |
| DE2610717C3 (de) | Hepatitis-B-Impfstoff und Verfahren zu seiner Herstellung | |
| DE2658170A1 (de) | Arzneimittel zur behandlung der durch den hepatitisvirus b ausgeloesten akuten oder chronischen infektionen | |
| DE2617870C2 (enrdf_load_stackoverflow) | ||
| DE3604947C2 (enrdf_load_stackoverflow) | ||
| DE19600939C1 (de) | Verfahren zur Trennung von IgG und IgA | |
| Barnes | Glomerular localization of platelet secretory proteins in mesangial proliferative lesions induced by habu snake venom. | |
| DE3005495C2 (de) | Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen | |
| DE2602892A1 (de) | Konzentriertes hepatitis-b-oberflaechenantigen enthaltende masse und verfahren zu ihrer herstellung | |
| DE69615015T2 (de) | Zusammensetzungen und verfahren zur detektion und behandlung des erworbenen immun-defizienz-syndroms | |
| DE2440926B2 (de) | lnjizierbarer 'inaktivierter Impfstoff gegen Hepatitis B und Verfahren zu seiner Herstellung | |
| AT226372B (de) | Dessaggregiertes Gammaglobulin und Verfahren zu seiner Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHA | Expiration of time for request for examination |